Vaginal discharge

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Retrieved on: 
Thursday, March 28, 2024
Cream, Dysmenorrhea, Patient, History, Bacteria, G&A, Vaginal discharge, IND, Bayer, Human development, Investment, Diclofenac, NSAID, Menstruation, Research, Hormone, Bacterial vaginosis, P-value, Webcast, SAN, NIH, Trial of the century, Pleasure, Woman, Breast cancer, Safety, Pharmacokinetics, Food, Development, Menopause, Nonsteroidal anti-inflammatory drug, HR, ARPA, VVA, Tamoxifen, FDA, Attention, CRADA, Female, Dyspareunia, Ecosystem, NICHD, Bangladesh Technical Education Board

SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2023 and provided a company update.

Key Points: 
  • In addition, we are excited about the increased attention that women’s health has received more broadly,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
  • In December 2023, Daré announced positive topline results from the Phase 1 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1.
  • Financial Highlights for the Year Ended December 31, 2023 and 2024 Projections
    Cash and cash equivalents: $10.5 million at December 31, 2023.
  • Daré will host a conference call and live webcast today, March 28, 2024, at 4:30 p.m. Eastern Time to review financial results for the year ended December 31, 2023 and to provide a company update.

Doctor's BiomeⓇ: Women's Health - Dietary Supplement Inhibited Pathogenic E. coli Bacteria and C. albicans Yeast

Retrieved on: 
Thursday, March 21, 2024
Food science, Urinary tract infection, Growth, Nutrition, Vaginal discharge, Health, Pelvic pain, Common, Journal, Candidiasis, UTI, Chills, Escherichia coli, Woman, Women's health, Infection, Fever, Urinary incontinence, Pain, Dietary supplement

Common UTI symptoms include urge and urinary incontinence, burning sensation while urinating, cloudy urine and pelvic pain.

Key Points: 
  • Common UTI symptoms include urge and urinary incontinence, burning sensation while urinating, cloudy urine and pelvic pain.
  • "Doctor's BiomeⓇ: Women's Health, is the first successful line extension of Doctor's BiomeⓇ.
  • Dr. Howard F. Robins, Chief Medical Officer of Doctor's BiomeⓇ explained "Our focus was to develop a proprietary dietary supplement for women that can inhibit both E. coli and C.
  • To develop Women's Health dietary supplement, we used Doctor's BiomeⓇ proprietary blend of five strains of Bifidobacteria and ten strains of Lactobacilli, as well as organic cranberry powder.

Hope for Women: Womed Unveils First Fertility Restoration Device Proven Effective in Randomized Clinical Trial

Retrieved on: 
Thursday, March 7, 2024
Research, Medical Devices, Women, Baby, Maternity, Clinical Trials, Health Technology, Biotechnology, Consumer, Health, Science, Hospital, Choix, Woman, Recurrence, Vaginal discharge, Multimedia, News, Uterus, Pain, Female, Safety, Obstetrics, Patient, Knowledge, Curettage, Infertility, IUA, Birth control

No device indicated for IUA prevention has been shown to be effective in this specific patient group.

Key Points: 
  • No device indicated for IUA prevention has been shown to be effective in this specific patient group.
  • PREG2 is an international, randomized clinical trial designed to measure Womed Leaf's effectiveness.
  • 160 women with severe or moderate IUA were randomly assigned to receive a Womed Leaf or not after adhesiolysis surgery.
  • "Womed Leaf, which is already registered in Europe and Brazil, will be marketed through commercial partners."

Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd's Commercial Launch of VIVJOA® (Oteseconazole) Capsules for the Treatment of Severe Vulvovaginal Candidiasis (VVC) in China

Retrieved on: 
Wednesday, February 7, 2024
Partnership, Oteseconazole, Vaginal discharge, Red, Candidiasis, Capsule, Irritation, CYP, Fluconazole, Yeast, Patient, National Medical Products Administration, Azole, Enzyme, FDA, Candida albicans, Excipient, Dyspareunia, Vaginal yeast infection, Hypersensitivity, Combustion, Fissure, CYP51, Woman, Pharmaceutical industry

DURHAM, N.C., Feb. 7, 2024 /PRNewswire/ -- Mycovia Pharmaceuticals, Inc. ("Mycovia"), an emerging biopharmaceutical company, today announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd ("Hengrui") has commercially launched VIVJOA® (oteseconazole) in China, making available an innovative oral azole antifungal indicated for the treatment of severe vulvovaginal candidiasis (VVC). VIVJOA is contraindicated for females of reproductive potential, pregnant and lactating women, and patients with known hypersensitivity to active ingredients, excipients, and azoles.

Key Points: 
  • VIVJOA is contraindicated for females of reproductive potential, pregnant and lactating women, and patients with known hypersensitivity to active ingredients, excipients, and azoles.
  • "The disease burden in China is significant, and access to VIVJOA provides health care providers and women suffering with severe VVC a new treatment option."
  • Vulvovaginal candidiasis is an exceedingly common mucosal infection usually caused by Candida albicans but can occasionally be caused by other Candida species or yeasts.
  • In April 2022, the U.S. Food and Drug Administration (FDA) approved VIVJOA (oteseconazole) Capsules as the first medication for Recurrent Vulvovaginal Candidiasis (RVVC, or chronic yeast infection).

Knight Therapeutics Announces Product Launch for IMVEXXY® in Canada

Retrieved on: 
Thursday, January 4, 2024
Quality of life, Woman, GUD, Estradiol, Pain, Menopause, Dry, Dyspareunia, Therapy, Vaginal discharge, VVA, Ageing, Common, Health Canada, TSX, Patient, Birth control

MONTREAL, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of IMVEXXY® in Canada.

Key Points: 
  • MONTREAL, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of IMVEXXY® in Canada.
  • “We are very excited about the launch of IMVEXXY®, a new treatment option for postmenopausal women in Canada.
  • Knight and TherapeuticsMD signed a license agreement in July 2018 pursuant to which TherapeuticsMD granted Knight the exclusive Canadian commercialization rights to IMVEXXY® (estradiol vaginal inserts).
  • Under the terms of the license agreement related to IMVEXXY® in Canada, Knight will pay TherapeuticsMD sales milestone fees and royalties based upon certain aggregate annual sales of IMVEXXY® in Canada.

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Retrieved on: 
Thursday, November 9, 2023
Cream, Female, FDA, Bacterial vaginosis, Research, Human development, Trial of the century, Cooperative research and development agreement, Vaginal discharge, Food, Hot, Organon, Human services, Eunice Kennedy Shriver National Institute of Child Health and Human Development, G&A, Progesterone, Phase 3, Quarter, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Call, Development, NICHD, Webcast, Clinical trial, ID, Tamoxifen, FSAD, Bacteria, Hormone, NIH, Woman, Safety, Office of Inspector General, U.S. Department of Health and Human Services, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Patient, Bangladesh Technical Education Board, Pharmaceutical industry, Birth control, Bayer, Conference

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended September 30, 2023 and provided a company update.

Key Points: 
  • ET
    SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended September 30, 2023 and provided a company update.
  • XACIATO™ provides a new therapeutic option for the millions of women suffering from bacterial vaginosis in the U.S.
  • Financial Highlights for the Quarter ended September 30, 2023
    Cash and cash equivalents: $13.8 million at September 30, 2023.
  • Daré will host a conference call and live webcast today, November 9, 2023, at 4:30 p.m. Eastern Time to review financial results for the quarter ended September 30, 2023 and to provide a company update.

Dr. Wolff's Vagisan Introduces Hormone-Free Moisturising Cream and Moisturising Cremolum, Clinically Proven to Soothe Vaginal Dryness

Retrieved on: 
Thursday, October 19, 2023
Cream, Lubrication, Vaginal discharge, Ageing, Menopause, Family, Vagina, Itch, Skin, Combustion, Friends, Climacteric, AIP, Quality of life, Lipid, International Menopause Society, Risk, Moisturizer, Dry, Woman, Safety, Elasticity, Personal lubricant, Pain, Douche, Kong, Birth control

Hong Kong SAR, China--(Newsfile Corp. - October 19, 2023) - Dr. Wolff's Vagisan introduces hormone-free Moisturising Cream and Moisturising Cremolum for women troubled by vaginal dryness while experiencing menopause.

Key Points: 
  • Hong Kong SAR, China--(Newsfile Corp. - October 19, 2023) - Dr. Wolff's Vagisan introduces hormone-free Moisturising Cream and Moisturising Cremolum for women troubled by vaginal dryness while experiencing menopause.
  • Vaginal secretions gradually decrease as a woman ages, resulting in decreased lubrication and elasticity of the vaginal tissue.
  • This can result in vaginal dryness and associated symptoms such as dryness, itching, burning, and pain3.
  • Vaginal hormone-free moisturising cream is not inferior to an estriol cream for treating symptoms of vulvovaginal atrophy: Prospective, randomised study.

Dr. Wolff Group: Dr. Wolff’s Vagisan introduces hormone-free Moisturising Cream and Moisturising Cremolum, clinically proven to soothe vaginal dryness

Retrieved on: 
Thursday, October 26, 2023
Cream, Lubrication, Vaginal discharge, Ageing, Menopause, Family, Itch, Skin, Combustion, Vagina, Friends, Climacteric, AIP, Quality of life, Lipid, International Menopause Society, Risk, Moisturizer, Dry, Woman, Safety, Elasticity, SAR, Personal lubricant, Pain, Douche, Birth control, Cosmetics

Dr. Wolff Group: Dr. Wolff’s Vagisan introduces hormone-free Moisturising Cream and Moisturising Cremolum, clinically proven to soothe vaginal dryness

Key Points: 
  • Dr. Wolff Group: Dr. Wolff’s Vagisan introduces hormone-free Moisturising Cream and Moisturising Cremolum, clinically proven to soothe vaginal dryness
    The issuer is solely responsible for the content of this announcement.
  • Dr. Wolff’s Vagisan introduces hormone-free Moisturising Cream and Moisturising Cremolum, clinically proven to soothe vaginal dryness
    HONG KONG SAR - Media OutReach - 18 October 2023 - Many woman experiencing menopause are troubled by vaginal dryness.
  • This can result in vaginal dryness and associated symptoms such as dryness, itching, burning, and pain3.
  • Vaginal hormone-free moisturising cream is not inferior to an estriol cream for treating symptoms of vulvovaginal atrophy: Prospective, randomised study.

Global Power Equipment Batteries Market Outlook & Forecast Report 2023-2028: Precision Manufacturing Drives Power Equipment Batteries Demand in High-Tolerance Industries - ResearchAndMarkets.com

Retrieved on: 
Monday, September 11, 2023
Energy, Other Energy, Other Manufacturing, Manufacturing, Semiconductor, IEA, Electronics, Vaginal discharge, International Energy Agency, Research, TTI, DIY, Stanley Black & Decker, Wood, Electrical discharge machining, Kilowatt-hour, Growth, EDM, Electric battery, Woodworking, EV

The "Power Equipment Batteries Market - Global Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Power Equipment Batteries Market - Global Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global power equipment batteries market is expected to reach a value of $7.85 billion by 2028 from $5.6 billion in 2022, growing at a CAGR of 5.80% from 2022 to 2028
    The global power equipment batteries market is characterized by low market concentration and high competition among players.
  • These advances have supported the development of innovative and sophisticated cordless power tools and propelled the demand for power equipment batteries.
  • Thus, using such power tools in these industries will also stir the demand for power equipment batteries.

Global Power Equipment Batteries Market Report 2023: A $7.85 Billion Market by 2028 - Focus on Asian Manufacturing's Rising Influence & Industry 4.0 and Smart Manufacturing Trends

Retrieved on: 
Friday, September 1, 2023
Semiconductor, IEA, Electronics, Vaginal discharge, International Energy Agency, Research, TTI, DIY, Stanley Black & Decker, Wood, Electrical discharge machining, Kilowatt-hour, Growth, EDM, Electric battery, Woodworking, EV

DUBLIN, Sept. 1, 2023 /PRNewswire/ -- The "Power Equipment Batteries Market - Global Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 1, 2023 /PRNewswire/ -- The "Power Equipment Batteries Market - Global Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global power equipment batteries market is expected to reach a value of $7.85 billion by 2028 from $5.6 billion in 2022, growing at a CAGR of 5.80% from 2022 to 2028
    The global power equipment batteries market is characterized by low market concentration and high competition among players.
  • These advances have supported the development of innovative and sophisticated cordless power tools and propelled the demand for power equipment batteries.
  • Equipment types of the powered equipment batteries market can be categorized as a driller, chainsaw, lawn mower, impact wrench, and other equipment.